CareLit Fachartikel
Efficacy and safety of infliximab in patients with ulcerative colitis refractory to steroids and immunosuppressive agents
M Jürgens, T Ochsenkühn, S Brand, S Pfennig, C Tillack, B Göke, J Seiderer · Zeitschrift für Gastroenterologie · 2008 · Heft 10
Dokument
1134848
CareLit-ID
Jahr
2008
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Introduction: Infliximab (IFX; Remicade, Schering Plough), a chimeric monoclonal antibody targeting TNF-α, represents the first biological approved for treatment of ulcerative colitis (UC). In order to evaluate the efficacy and safety of IFX in UC, we retrospectively analyzed the effect of IFX on induction and maintenance of remission, prevention of colectomy and safety in UC patients, refractory to steroids and immunosuppressive agents. Methods: All patients treated with immunosuppressive therapy with azathioprine or 6-mercaptopurine presenting with moderate to severe UC (Lichtiger score CAI 5–15) in our IBD ce…
Schlagworte
After
Mercaptopurine
Data Analysis
Azathioprine
Arthralgia
Depression
Zeitschrift für Gastroenterologie
